Skip to main content

Table 4 Characteristics associated with full publication: Cox proportional hazards model analysis

From: Publication statuses of clinical trials supporting FDA-approved immune checkpoint inhibitors: a meta-epidemiological investigation

  HR (95% CI) P-value
Drug type
 ICPi ref.  
 Other anticancer drugs 1.1 (0.8–1.7) 0.55
Study phase
 Phase 1 ref.  
 Phase 2 or 3 1.7 (1.1–2.6) 0.02
Multi-country study
 No ref.  
 Yes 1 (0.4–2.2) 0.95
Sample size
 Smaller ref.  
 Larger 1.4 (0.8–2.2) 0.16
  1. ICPi immune checkpoint inhibitor, HR hazard ratio, CI confidence interval, ref. reference
\